ONCAlert | Upfront Therapy for mRCC

Renal Cell Carcinoma VIEW MORE >>

All patients with advanced renal cell car­cinoma assigned to nivolumab plus ipilimumab in the phase III CheckMate 214 trial had a longer treatment-free survival than patients treated with sunitinib. Furthermore, those patients assigned to the combination spent less time experiencing treatment-related adverse events.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.